Docetaxel and Prednisone (DP) for Advanced Prostate Cancer

Tannock I.F. , de Wit R. , Berry W.R. .; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15): 1502–1512.

Berthold D.R. , Pond G.R. , Soban F. , de Wit R. , Eisenberger M. , Tannock I.F. Docetaxel plus prednisone or mitoxantrone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 2(10): 242–245.

Dagher R. , Ning L. , Abraham S. , Rahman A. , Sridhara R. , Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res. 2004; 10(24): 8147–8151.

Saad F. , Ruether D. , Ernst S. . Canadian Uro-Oncology Group. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int. 2008; 102(5): 551–555.

Zhang H.L. , Ye D.W. , Yao X.D. . Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Urol Int. 2007; 79(4): 307–311.

Machiels J.P. , Mazzeo F. , Clausse M. . Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2008; 26(32): 5261–5268.

Shimazui T. , Kawai K. , Miyanaga N. . Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol. 2007; 37(8): 603–608.

Fosså S.D. , Jacobsen A.B. , Ginman C. . Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol. 2007; 52(6): 1691–1698.

Patel A.R. , Sandler H.M. , Pienta K.J. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin Genitourin Cancer. 2005; 4(3): 212–214.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer. v.2.2009. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Published 2009. Accessed December 8, 2009.

Winquest E. , Waldron T. , Berry S. , Ernst D.S. , Hotte S. , Lukka H. ; Genitourinary Cancer Disease Site Group. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer: a clinical practice guideline. http://www.cancercare.on.ca/pdf/pebc3-15f.pdf. Published November 1, 2005. Accessed December 8, 2009.

Basch E.M. , Somerfield M.R. , Beer T.M. . American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007; 25(33): 5313–5318.

Institute for Safe Medication Practices. FDA Advise-ERR: Medication errors associated with Taxotere and Taxol ISMP Medication Safety Alert! Acute Care Edition. http://www.ismp.org/Newsletters/acutecare/articles/19970924.asp. Published February 7, 2001.

Savarese D. , Taplin M.E. , Halabi S. . A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B Trial 9780. Semin Oncol. 1999; 26(5)(suppl 17):39–44.

Hesketh P.J. , Kris M.G. , Grunberg S.M. . Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15(1): 103–109.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis. v.4.2009. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Published 2009. Accessed December 8, 2009.

Kris M.G. , Hesketh P.J. , Somerfield M.R. . American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24(18): 2932–2947.

Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. 2008. http://data.memberclicks.com/site/mascc/MASCC_Guidelines_Update.pdf. Updated March 2008. Accessed December 8, 2009.

Terrey J.P. , Aapro M.S. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996; 8: 281–288.

Carmichael J. , Keizer H.J. , Cupissol D. , Milliez J. , Scheidel P. , Schindler A.E. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998; 9(5): 381–385.

de Wit R. , de Boer A.C. , vd Linden G.H. , Stoter G. , Sparreboom A. , Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001; 19; 85(8):1099–1101.

Smith IE; the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol. 1993; 119(6): 350–354.

Soukop M; Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer. 1994; 2(3): 177–183.

Weiss R.B. Hypersensitivity reactions. Semin Oncol. 1992; 19(5): 458–477.

Zanotti K.M. , Markham M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf. 2001; 24(10): 767–779.

Taxotere [package insert]. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals Inc; 2008.

Smith T.J. , Khatcheressian J. , Lyman G.H. . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19): 3187–3205.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myeloid growth factors. v.1.2009. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Published 2009. Accessed December 8, 2009.

Larson D.L. Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49(9): 1796–1799.

Larson D.L. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg. 1985; 75(3): 397–405.

Mullin S. , Beckwith M.C. , Tyler L.S. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000; 35: 57–74.

Aronoff G.R. , Bennett W.M. , Berns J.S. . Drug Prescribing in Renal Failure. 5th ed. Philadelphia, PA: American College of Physicians; 2007.

Boyiadzis M.M. , Lebowitz P.F. , Frame J.N. , Fojo T. Hematology-Oncology Therapy. New York, NY: McGraw-Hill; 2007: 570–578.

Floyd J. , Mirza I. , Sachs , Perry M.C. Hepatotoxicity of chemotherapy. Semin Oncol. 2006; 33: 50–67.

King P.D. , Perry M.C. Hepatotoxicity of chemotherapy. Oncologist. 2001; 6(2): 162–176.